Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28137126 | 0.84 | ASIC3 (0.55) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL10263631 | 0.84 | PNMT (0.63) | PNMTADRA2AADRA2BADRA2CNOS3 | |
| SCHEMBL10275788 | 0.83 | ALDH1A1 (0.34) | PNMTALDH1A1HTT | |
| SCHEMBL17813289 | 0.78 | PNMT (0.43) | PNMTDDB1CRBNADRA2AADRA2B | |
| SCHEMBL16409854 | 0.75 | PNMT (0.42) | PNMTDDB1CRBNADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL16394225 | 0.74 | PNMT (0.41) | PNMTDDB1CRBNADRA2AADRA2B | |
| SCHEMBL28154990 | 0.72 | PNMT (0.43) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL13063374 | 0.71 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CALDH1A1HTT | |
| SCHEMBL22682041 | 0.71 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL19675288 | 0.69 | DRD2 (0.37) | PNMTDDB1CRBNADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | PNMT 1016/4885DDB1 1287/4885CRBN 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.